27,200 Shares in Immunome, Inc. $IMNM Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) in the second quarter, HoldingsChannel reports. The institutional investor acquired 27,200 shares of the company’s stock, valued at approximately $576,000.

A number of other large investors have also added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Immunome during the 2nd quarter valued at $186,588,000. Primecap Management Co. CA bought a new position in shares of Immunome during the second quarter valued at $97,081,000. California State Teachers Retirement System boosted its position in shares of Immunome by 1,958.0% during the second quarter. California State Teachers Retirement System now owns 2,293,478 shares of the company’s stock valued at $48,599,000 after buying an additional 2,182,034 shares during the last quarter. Sofinnova Investments Inc. increased its holdings in Immunome by 271.2% in the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after buying an additional 1,182,426 shares in the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in Immunome in the 4th quarter worth about $16,745,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Insider Transactions at Immunome

In related news, insider Robert Lechleider sold 55,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $22.62, for a total value of $1,244,100.00. Following the transaction, the insider owned 15,805 shares of the company’s stock, valued at approximately $357,509.10. This trade represents a 77.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 101,050 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00. Following the completion of the transaction, the director directly owned 308,504 shares in the company, valued at approximately $6,515,604.48. The trade was a 24.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 622,310 shares of company stock worth $14,581,766 in the last quarter. Company insiders own 7.21% of the company’s stock.

Immunome Stock Performance

Immunome stock opened at $24.55 on Tuesday. Immunome, Inc. has a one year low of $8.93 and a one year high of $30.06. The stock has a fifty day moving average of $25.34 and a 200 day moving average of $22.73. The stock has a market cap of $2.79 billion, a PE ratio of -9.70 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, sell-side analysts predict that Immunome, Inc. will post -2.38 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on IMNM shares. Citigroup restated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Truist Financial boosted their price objective on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Wall Street Zen downgraded shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Barclays assumed coverage on shares of Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.64.

Immunome Profile

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.

Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.